Literature DB >> 32567023

Genetic associations and serum paraoxonase levels with atherosclerosis in western Iranian patients.

Gholamreza Shahsavari1, Negar Nouryazdan2, Glavizh Adibhesami3, Mehdi Birjandi4.   

Abstract

The oxidative modification of low-density lipoprotein (LDL) in the arterial wall plays a pivotal role in the initiation and progression of atherosclerosis which is a complex and progressive disorder. Paraoxonase1 (PON1), which is required for lipid metabolism, is believed to protect LDL from oxidation. The relationship between PON1 gene Leusin55Methionin (L55M) and Glutamine192Arginine (Q192R) polymorphisms in western Iranians with atherosclerosis and its association with enzyme activity and oxidized low-density lipoprotein (oxLDL) were examined in the present study. In this study, blood specimens were collected from 145 healthy individuals and 154 patients with atherosclerosis proven by angiography referred to Shahid Madani Hospital, Khorramabad, Iran. Genomic deoxy ribonucleic acid (DNA) was extracted from whole blood. For all the subjects, restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) was carried out for the detection of L55M and Q192R polymorphisms. PON1 enzyme activity and the level of oxLDL were also evaluated. There was a 3.114-fold increase in the risk of developing atherosclerosis in the subjects presenting the PON1L55M, MM genotype compared to those with the LL genotype (OR 3.114; 95% CI 1.412-6.870). PON1Q192R polymorphism in the PON1 gene was not associated with atherosclerosis. Patients with atherosclerosis had significantly higher oxLDL and reduced PON1 enzyme activity (P < 0.05) compared to the controls. There was no association between the type of genotype, enzyme activity, and oxLDL level. It has been concluded that PON1L55M polymorphism and MM genotype are associated with an increased risk of coronary artery disease (CAD) in Iranian patients with atherosclerosis. We did not find any relationship between PON1Q192R polymorphism and atherosclerosis.

Entities:  

Keywords:  Coronary arteriosclerosis; High-density lipoproteins (HDL); Oxidized low-density lipoprotein (oxLDL); Paraoxonase 1 (PON1); Single-nucleotide polymorphism (SNP)

Mesh:

Substances:

Year:  2020        PMID: 32567023     DOI: 10.1007/s11033-020-05585-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  5 in total

1.  The Role of Paraoxonase 1 (PON1) Gene Polymorphisms in Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Authors:  Sana Ashiq; Kanwal Ashiq
Journal:  Biochem Genet       Date:  2021-02-18       Impact factor: 1.890

2.  Association of Paraoxonase-1 Genotype and Phenotype with Angiogram Positive Coronary Artery Disease.

Authors:  Sara Saffar Soflaei; Mojtaba Baktashian; Kiana Hosseinpour Moghaddam; Maryam Saberi-Karimian; Negin Kosari; Seyed Mohammad Hashemi; Mohsen Mouhebati; Mahsa Amini; Mashallah Dehghani; Habibollah Esmaily; Mahmoud Ebrahimi; Homa Falsoleiman; Abolfazl Nosrati-Tirkani; Fatemeh Sadabadi; Gordon A Ferns; Mansoor Salehi; Alireza Pasdar; Majid Ghayour-Mobarhan
Journal:  Arq Bras Cardiol       Date:  2022-09-02       Impact factor: 2.667

Review 3.  The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases.

Authors:  Anna Wysocka; Agnieszka Zwolak
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

4.  Genetic Association of rs10757278 on Chromosome 9p21 and Coronary Artery Disease in a Saudi Population.

Authors:  Neda Bogari; Anas Dannoun; Mohammad Athar; Osama Elkhateeb; Massimo Porqueddu; Reem Allam; Francesco Alamanni
Journal:  Int J Gen Med       Date:  2021-05-05

5.  Paraoxonase 1 gene variants concerning cardiovascular mortality in conventional cigarette smokers and non-smokers treated with hemodialysis.

Authors:  Alicja E Grzegorzewska; Kamila Ostromecka; Monika K Świderska; Paulina Adamska; Adrianna Mostowska; Paweł P Jagodziński
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.